We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Molecular POC Market to Reach USD 510 Million by 2023

By LabMedica International staff writers
Posted on 27 Feb 2018
Print article
The molecular point-of-care market (POC), consisting of systems with molecular capability used in decentralized test environments, was worth an estimated USD 165 million in 2017 and is expected to continue growing in the double-digits to reach USD 510 million in 2023.

The key growth areas in molecular POC diagnostics are expected to be influenza testing, hospital-acquired infections and sexually transmitted diseases. Pricing remains a challenge for molecular systems, although the advantages they offer paint a bright long-term outlook for the market. PCR or sequencing based systems in decentralized settings are expected to grow at the fastest pace, in terms of revenue, as compared to other IVD market categories.

These are the latest findings of Kalorama Information, (New York, NY, USA), an independent medical market research firm.

Molecular point-of-care solutions now offer multiplexing capabilities, allowing an assay to detect multiple pathogenic targets for an infectious condition, in a single run. Multiplex assays for respiratory infections are more common, targeting multiple flu viruses and strains as well as respiratory syncytial virus, among others. Test panels are available for detecting multiple possible causes of gastrointestinal infection, sepsis, or even multiple tropical disease agents such as Ebola, Dengue, Chikungunya, malaria, and so on. It is also possible to design assays for targeting specific genes generally associated with non-infectious diseases such as cancer or Alzheimer's disease, or to determine a patient's sensitivity or resistance to pharmaceutical treatments.

According to Kalorama, influenza and respiratory is the key area of molecular POC diagnostics with a share of almost 40% and is expected to continue dominating the market until 2023. However, immunoassay POC has not exhibited a visible decline in revenue growth and continues to witness innovations. Even in influenza testing, which is the mainstay of molecular POC testing, immunoassay has not witnessed a decline from the presence of molecular testing.

"Just as when molecular test systems were first introduced, huge predictions settled down to reasonable ones, 15 years ago, so it is with the point of care version." said Bruce Carlson, Publisher of Kalorama Information. "This is a market with high potential and investor interest was justified, but healthcare organizations are judicious about purchasing and the technology will have to prove. There's also side benefits to these technologies, where large IVD players can present the system as complete package of laboratory equipment, down to POC level and that should continue to benefit the major players in molecular POC."

Related Links:
Kalorama Information

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.